ClinicalTrials.gg
RecruitingNCT06415487Updated Jul 1, 2025

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

A Phase 1 interventional study of Cyclophosphamide and Fludarabine in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Acepodia Biotech, Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Acepodia Biotech, Inc. · Phase 1, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 172 studies in Neoplasm Metastasis with a site in Taiwan — 32 open to participants now, 64 under way, 30 of them phase 3. Neoplasm Metastasis · Taiwan.

Planned enrollment
133rd of 154
30 · median 306
Started
2024
with 10 others
Phase 1
28 of 172
8 open now
Primary completion
2026-12
later than 25 of 63 live
Registered
151st of 172
by date

Among the 172 studies in Neoplasm Metastasis with a site in Taiwan, this one is the 133rd largest by planned enrollment of the 154 interventional ones that give a count, is one of 11 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 25 of the 63 other live ones, and was the 151st registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

32 of the 172 studies in Neoplasm Metastasis with a site in Taiwan are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Neoplasm Metastasis with a site in Taiwan, or all of them as a file.
02

Study summary

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced unresectable or solid tumors that have failed at least two (one of which must be targeted therapy)
  • At least one as defined by v1.1 criteria
  • (ECOG) Performance Status 0-1
  • Adequate hematologic and renal, hepatic and cardiac function
  • Oxygen saturation via pulse oximeter ≥92% at rest on room air

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a genetically modified cell therapy product targeting EGFR
  • History of transplantation
  • Subjects with active
  • History or presence of Central Nervous System (CNS) disorder (e.g. epilepsy)
  • Clinically significant active infection
  • (HIV) infection, active infection, or infection.
  • History of with the exception of certain treated malignancies with no evidence of disease.
  • Primary immunodeficiency disorder
  • Pregnant or lactating female
  • Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment or comply with study requirements, including understanding and rendering of
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ACE2016 ONLY: 1 DOSE

    ACE2016 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating doses of ACE2016.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: ACE2016

  • Experimental
    ACE2016 ONLY: 3 DOSES

    ACE2016 recommended dose, monotherapy. Lymphodepleting regimen followed by recommended dose of ACE2016.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: ACE2016

  • Experimental
    ACE2016 AND PEMBROLIZUMAB: 3 DOSES

    ACE2016 recommended dose, in combination with pembrolizumab. Lymphodepleting regimen followed by recommended dose of ACE2016, giving in combination with pembrolizumab.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: ACE2016 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs, AESIs, Grade 3 or higher TEAEs, TEAEs considered related to ACE2016, TEAEs resulting in death, SAEs, related SAEs, and TEAEs leading to treatment discontinuation will be summarized by cohort

    Time frame: 1 year

  2. Change from baseline in clinical laboratory tests results

    Number of subject with change from baseline clinical significant lab findings by cohort (descriptive)

    Time frame: 1 year

  3. Change from baseline in vital signs results

    Number of subjects with change from baseline clinical significant vital signs findings by cohort (descriptive)

    Time frame: 1 year

  4. Recommended Dose (RD)

    Time frame: 1 year

Secondary outcomes

  1. Persistence of ACE2016 before and after administration

    Half-life of ACE2016

    Time frame: 1 year

  2. Measure of anti-ACE2016 antibodies after administration

    Titration of anti-ACE2016 antibodies after administration

    Time frame: 1 year

  3. Objective Response Rate (ORR)

    Proportion of subjects assessed as having a complete response (CR) or partial response (PR) according to RECIST v1.1

    Time frame: 1 year

  4. Disease Control Rate (DCR)

    Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD) as defined by RECIST v1.1

    Time frame: 1 year

  5. Duration Of Response (DOR)

    Duration (time) from the first tumor assessment showing response per RECIST v1.1 to the time of disease progression or death.

    Time frame: 1 year

  6. Progression Free Survival (PFS)

    Duration (time) from first ACE2016 cell infusion to first documentation of disease progression per RECIST v1.1 or death

    Time frame: 1 year

Other outcomes

  1. Pharmacodynamics of ACE2016

    Change from baseline IL2,6,8,10 IFN TNF, and change in TBNK cell subsets.

    Time frame: 1 year

  2. gdT infiltration in tumor mass

    Optional biopsy to examine gdT cell infiltration

    Time frame: 1 year

07

Study locations

4 of 9 sites recruiting
  • University of California San Diego
    San Diego, California 92093, United States
    Recruiting
    • Moores Cancer Center · Contact
    • Sandip Patel, MD · Principal investigator
  • SCRI Denver Drug Development Unit
    Denver, Colorado 80218, United States
    Recruiting
    • James Vick · Contact
    • Jason Henry, MD · Principal investigator
  • Sarah Cannon Research Institute (SCRI) Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Emily Lay Petcu · Contact
    • Meredith Pelster, MD · Principal investigator
  • Texas Oncology
    Dallas, Texas 75246, United States
    Recruiting
    • Texas Oncology · Contact
    • Scott Paulson, MD · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, Beitou District 112, Taiwan
    Not yet recruiting
    • Taipei Veterans General Hospital · Contact
    • Muh-Hwa Yang, MD · Principal investigator
  • Chang Gung Medical Foundation Linkou
    Taoyuan City, Guishan District 3333, Taiwan
    Not yet recruiting
    • Chang Gung Medical Foundation · Contact
    • Wen-Cheng Chang, MD · Principal investigator
  • Taipei Medical University-Shuang Ho Hospital
    New Taipei City, Zhonghe District 235, Taiwan
    Not yet recruiting
    • Taipei Medical University · Contact
    • Kang-Yun Lee, MD · Principal investigator
  • Mackay Memorial Hospital Taipei
    Taipei, Zhongshan District 104, Taiwan
    Not yet recruiting
    • Mackay Memorial · Contact
    • Nai-Wen Su, MD · Principal investigator
  • Taichung Veteran General Hospital
    Taichung, 40705, Taiwan
    Not yet recruiting
    • Taichung Veteran General Hospital · Contact
    • Kuan-Der Lee, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 28 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 16, 2024
StartActual
Aug 22, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 27, 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06415487
Lead sponsor
Acepodia Biotech, Inc.
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Aug 22, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 27, 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Stephanie Chien
Contact
clinical@acepodiabio.com
+1 415 366 7822

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion